Article
HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials.
The Journal of pathology - 1 Mar 2016
Richman Susan D, Southward Katie, Chambers Philip, Cross Debra, Barrett Jennifer, Hemmings Gemma, Taylor Morag, Wood Henry, Hutchins Gordon, Foster Joseph M, Oumie Assa, Spink Karen G, Brown Sarah R, Jones Marc, Kerr David, Handley Kelly, Gray Richard, Seymour Matthew, Quirke Philip
Abstract excerpt
HER2 overexpression/amplification is linked to trastuzumab response in breast/gastric cancers. One suggested anti-EGFR resistance mechanism in colorectal cancer (CRC) is aberrant MEK-AKT pathway activation through HER2 up-regulation. We assessed HER2-amplification/overexpression in stage II-III and IV CRC patients, assessing relationships to KRAS/BRAF and outcome. Pathological material was obtained from 1914...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.